{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:32:16Z","timestamp":1759483936119,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.cpcardiol.2020.100616","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T06:45:06Z","timestamp":1589870706000},"page":"100616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis-Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Adrian","family":"daSilva-deAbreu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bracamonte-Baran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose F.","family":"Condado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilis","family":"Babaliaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Tafur-Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy A.","family":"Mandras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2020.100616_bib0001","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1378\/chest.120.3.866","article-title":"Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension","volume":"120","author":"Preston","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0002","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1378\/chest.130.5.1481","article-title":"Sarcoidosis-associated pulmonary hypertension: Outcome with long-term epoprostenol treatment","volume":"130","author":"Fisher","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.healun.2007.11.576","article-title":"Pulmonary hypertension in end-stage pulmonary sarcoidosis: Therapeutic effect of sildenafil?","volume":"27","author":"Milman","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0004","first-page":"110","article-title":"Inhaled iloprost for sarcoidosis associated pulmonary hypertension","volume":"26","author":"Baughman","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0005","first-page":"139","article-title":"Ambrisentan for sarcoidosis associated pulmonary hypertension","volume":"28","author":"Judson","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0006","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1086\/688775","article-title":"Tadalafil therapy for sarcoidosis-associated pulmonary hypertension","volume":"6","author":"Ford","year":"2016","journal-title":"Pulm Circ"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0007","first-page":"A5700","article-title":"Outcomes of patients with pulmonary hypertension associated with sarcoidosis treated with epoprostenol","volume":"197","author":"Hon","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0008","first-page":"A6409","article-title":"Prostacyclin and oral vasodilator therapy in sarcoidosis associated pulmonary hypertension","volume":"191","author":"Bonham","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0009","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12471-016-0847-1","article-title":"Pulmonary hypertension complicating pulmonary sarcoidosis","volume":"24","author":"Huitema","year":"2016","journal-title":"Neth Heart J"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0010","article-title":"Sarcoidosis-associated pulmonary hypertension: an updated review and discussion of the clinical conundrum","author":"daSilva-deAbreu","year":"2019","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0011","first-page":"281","article-title":"Pulmonary stenting for the treatment of sarcoid induced pulmonary vascular stenosis","volume":"33","author":"Condado","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0012","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.hlc.2007.12.006","article-title":"Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis","volume":"18","author":"Hamilton-Craig","year":"2009","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0013","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/crj.12435","article-title":"Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension","volume":"11","author":"Liu","year":"2017","journal-title":"Clin Respir J"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018768289","article-title":"A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension","volume":"8","author":"Bazmpani","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01502-2017","article-title":"Balloon pulmonary angioplasty in sarcoid-related pulmonary hypertension","volume":"51","author":"Tramper","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0016","first-page":"256","article-title":"Sarcoidosis with major airway, vascular and nerve compromise","volume":"20","author":"Sekiguchi","year":"2013","journal-title":"Can Respir J"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0017","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0018","unstructured":"Centre WHO-UM. The use of the WHO-UMC system for standardised case causality assessment. The Uppsala Monitoring Centre [cited 209 Dec 20] Available from: https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf."},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0019","unstructured":"Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 209 Dec 20] Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1747-0803.2010.00387.x","article-title":"Results of intravascular stent placement for fibrosing mediastinitis","volume":"5","author":"Ferguson","year":"2010","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0021","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccm.2008.03.010","article-title":"Pulmonary hypertension caused by sarcoidosis","volume":"29","author":"Diaz-Guzman","year":"2008","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.cpcardiol.2020.100616_bib0022","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.201206-1137ED","article-title":"The 6-minute walk test in pulmonary arterial hypertension: how far is enough?","volume":"186","author":"Rubin","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.cpcardiol.2020.100616_bib0023","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CPM.0b013e318150c9a6","article-title":"Pulmonary hypertension related to respiratory disease","volume":"14","author":"Mathai","year":"2007","journal-title":"Clin Pulm Med"},{"issue":"25 Suppl","key":"10.1016\/j.cpcardiol.2020.100616_bib0024","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1016\/j.jacc.2013.10.036","article-title":"Pulmonary hypertension in chronic lung diseases","volume":"62","author":"Seeger","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280620300931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280620300931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:30:46Z","timestamp":1758940246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280620300931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0146280620300931"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100616","relation":{},"ISSN":["0146-2806"],"issn-type":[{"type":"print","value":"0146-2806"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis-Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100616"}}